Printer Friendly

CEPHALON LICENSES NOVEL PRODUCT TO TREAT NARCOLEPSY FROM LABORATOIRE L. LAFON

 WEST CHESTER, Pa. and PARIS, Feb. 1 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) of West Chester, Pennsylvania and Laboratoire L. Lafon of Paris announced today an agreement under which Cephalon receives the exclusive right to develop, market and sell modafinil in the United States and Mexico. The announcement came jointly from Frank Baldino, Jr., Ph.D., President and CEO of Cephalon, and Francois Lafon, CEO of Lafon.
 Modafinil is a synthetic compound developed by Lafon that acts selectively on the alpha adrenergic system in the brain. This system has been shown by leading scientists in the field to be involved with the etiology of narcolepsy, a debilitating, lifelong sleep disorder that is estimated to affect over 125,000 Americans. Results of a four-year series of European studies in more than 1,000 patients demonstrated that modafinil significantly reduced daytime sleep attacks and drowsiness seen in this disorder, while showing no adverse side effects. Subsequent to these trials, modafinil was judged by the French Ministry of Health to be safe and effective, receiving regulatory approval for narcolepsy in France in February 1992. Product sales in France will be initiated by Lafon upon receipt of pricing and reimbursement approval.
 "The acquisition of marketing rights for modafinil fits within the company's strategic objective to license in product opportunities directed toward neurologists," stated Dr. Frank Baldino, Jr. "Modafinil is a product with proven safety in man that has already gained French regulatory approval. The company is planning to perform a Phase III study in the U.S. to facilitate the filing of an NDA for marketing approval for the treatment of narcolepsy."
 Narcolepsy is a sleep disorder which has severe negative impacts on public safety, sense of self-worth, social image and the ability to retain a job. Symptoms of this disease often originate in late childhood and are most notably characterized by an uncontrollable propensity to fall asleep during the day. There is no cure for narcolepsy. Current therapies that treat disease symptoms, such as amphetamine-type stimulants, are often addictive and may have other side effects.
 Cephalon's results for the first quarter of 1993 will include a charge to earnings to reflect the payment made to Lafon upon execution of the agreement. Additionally, under the agreement Cephalon will purchase supplies of modafinil from Lafon and fund modafinil's clinical development in the U.S. and Mexico. The agreement also provides for royalty and certain other payments to Lafon.
 Mr. Francois Lafon commented that, "We are pleased to be working with a dynamic and focused company like Cephalon for the U.S. development and commercialization of modafinil." Founded in 1951, Lafon is a privately owned, research based, mid-size ethical pharmaceutical company in France. Lafon research specializes in discovery and development of innovative compounds, especially in CNS and cardiovascular therapies.
 Cephalon, Inc. is a leader in the development of products to treat neurological diseases and disorders. The company's primary focus is on neurodegenerative diseases which are characterized by the death of neurons, specialized conducting cells of the nervous system. The company has concentrated its research and development efforts on the prevention of neuronal death in several disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, head and spinal cord injuries, peripheral neuropathy, retinopathy, and stroke.
 -0- 2/1/93
 /CONTACT: Lyn Hyduke, assistant director of corporate communications of Cephalon, Inc., 215-344-0200; Karen L. Bergman of Burns McClellan, 212-505-1919, for Cephalon, Inc.; or Bill Mattson, 314-469-7600, for Laboratoire L. Lafon/
 (CEPH)


CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: LIC

SH -- NY015 -- 1197 02/01/93 09:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:588
Previous Article:LIFE SAVERS BRAND INTRODUCES NEW CANDY
Next Article:RADIX ANNOUNCES STEPHENS GROUP BECOMES LIMITED PARTNER
Topics:


Related Articles
CANADIAN LICENSE FOR NEW NEUROLOGY DRUG ACQUIRED BY DEPRENYL RESEARCH LIMITED FROM LABORATOIRE L. LAFON OF FRANCE
CEPHALON BEGINS MODAFINIL CLINICAL TRIAL IN UNITED STATES; EXPANDS MARKETING TERRITORY TO U.K. AND IRELAND
CEPHALON EXPANDS MARKETING TERRITORY FOR MODAFINIL
CEPHALON ANNOUNCES MODAFINIL PHASE III TRIAL RESULTS
CEPHALON ANNOUNCES SECOND POSITIVE PHASE III MODAFINIL STUDY IN NARCOLEPSY
Cephalon Submits New Drug Application For Modafinil to U.S. Food and Drug Administration
Cephalon Granted Approval to Market Provigil in the United Kingdom
Cephalon Launches PROVIGIL(R) (modafinil) in the United Kingdom
Cephalon and Dompe Sign Product Marketing Agreements for PROVIGIL And MYOTROPHIN in Italy
Cephalon Reacquires Rights to Modafinil in Major European Markets.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters